Results 211 to 220 of about 59,555 (264)
Some of the next articles are maybe not open access.
Immunoreactive Gastric Inhibitory Polypeptide*
Endocrine Reviews, 1988IN 1906 extracts of mucosa from the upper small intestine from pigs were tested as a treatment of diabetes in the hope that “the internal secretion of the pancreas might be stimulated and initiated by the substance of the nature of a hormone yielded by the duodenal mucous membrane” (1).
openaire +2 more sources
Clinical studies with gastric inhibitory polypeptide
World Journal of Surgery, 1979AbstractIntravenous infusion of porcine GIP in man induces insulin release when a degree of hyperglycemia is present. This glucose‐dependent insulinotropic response occurs when a dose of GIP is administered to obtain circulating levels of approximately 1 ng/ml, a physiologic level that can be achieved by the ingestion of glucose or corn oil or a mixed ...
J C, Brown, S, Otte
openaire +2 more sources
Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
Best Practice & Research Clinical Endocrinology & Metabolism, 2004The 42 amino acid polypeptide glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide (GIP) is released from intestinal K-cells in response to nutrient ingestion. Based on animal studies, the peptide was initially assumed to act as an endogenous inhibitor of gastric acid secretion.
Juris J. Meier, Michael A. Nauck
openaire +1 more source
Gastric Inhibitory Polypeptide (GIP)
1988Publisher Summary This chapter describes two apparently unrelated physiological phenomena for a single peptide that is gastric inhibitory polypeptide (GIP). These physiological actions are the inhibition of gastric acid secretion and stimulation of insulin release. GIP is a major hormone involved in the gastrointestinal regulation of insulin release,
J.C. Brown +2 more
openaire +1 more source
Gastric Inhibitory Polypeptide
Archives of Surgery, 1974Gastric inhibitory polypeptide (GIP), immunoreactive insulin (IRI), and glucose levels in response to orally administered glucose were determined in ten patients with vagotomy and pyloroplasty (V&P) and in 21 normal subjects. The V&P patients had the expected early and exaggerated increase in mean serum glucose with a subsequent decline to a level ...
N R, Thomford +4 more
openaire +2 more sources
Gastric Inhibitory Polypeptide: the neglected incretin revisited
Regulatory Peptides, 2002After the ingestion of fat- and glucose-rich meals, gut hormones are secreted into the circulation in order to stimulate insulin secretion. This so-called "incretin effect" is primarily conferred by Glucagon-like peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP).
Juris J, Meier +3 more
openaire +2 more sources
Conflicting gastric inhibitory polypeptide data: possible causes
Diabetes Research and Clinical Practice, 1993The literature with respect to GIP is flooded with conflicting data especially with respect to its role in type 2 diabetes mellitus, obesity, type 1 diabetes mellitus and chronic pancreatitis. This review describes possible reasons for the discrepancies which include species variation of GIP, heterogeneity of molecules with different immunoreactivity ...
M J, Alam, K D, Buchanan
openaire +2 more sources
Gastric Inhibitory Polypeptide (GIP) in Chronic Pancreatitis
The Journal of Clinical Endocrinology & Metabolism, 1976The plasma gastric inhibitory polypeptide (GIP), pancreatic glucagon-like immunoreactivity (PGLI), and gut glucagon-like immunoreactivity (GGLI) responses to oral glucose have been measured in five patients with chronic pancreatitis (with diabetic glucose tolerance tests) and in matched nondiabetic controls. Plasma GIP levels rise rapidly after glucose
J L, Botha, A I, Vinik, J C, Brown
openaire +2 more sources
The Insulinotropic Action of Gastric Inhibitory Polypeptide
Canadian Journal of Physiology and Pharmacology, 1975The effect of highly purified gastric inhibitory polypeptide (GIP) on immunoreactive insulin (IRI) secretion in the conscious fasted dog was investigated. Significant increases in IRI release were observed with intravenous administration of three different doses of GIP. These were accompanied by depression in fasting serum-glucose levels.
R A, Pederson, H E, Schubert, J C, Brown
openaire +2 more sources